Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic Analysis ASFRA:8V8 +16.76%34 PS Ratio is 1.88 as of Jul. 20, 2026, which is 32% below its 10-year median of 2.78. GuruFocus rates FRA:8V8 with a GF Score™ of 34/100 and a GF Value™ of €0.04. The stock has 4 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Genetic Analysis AS ranks better than 53.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Genetic Analysis AS's share price is €0.0432.
Genetic Analysis AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.02. Hence, Genetic Analysis AS's PS Ratio for today is 1.88.
Good Sign:
Genetic Analysis AS stock PS Ratio (=2.51) is close to 1-year low of 2.32.
The historical rank and industry rank for Genetic Analysis AS's PS Ratio or its related term are showing as below:
FRA:8V8'
s PS Ratio Range Over the Past 10 Years
Min: 1.07 Med: 2.78 Max: 71.77
Current: 2.51
During the past 7 years, Genetic Analysis AS's highest PS Ratio was 71.77. The lowest was 1.07. And the median was 2.78.
FRA:8V8's PS Ratio is ranked better than 53.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.72
vs FRA:8V8: 2.51
Genetic Analysis AS revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Genetic Analysis AS was -15.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -17.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.70% per year.
During the past 7 years, Genetic Analysis AS's highest 3-Year average Revenue per Share Growth Rate was 17.10% per year. The lowest was -17.30% per year. And the median was 11.50% per year.
Back to Basics: PS Ratio
Genetic Analysis AS (FRA:8V8) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Genetic Analysis AS PS Ratio Related Terms
Genetic Analysis AS PS Ratio Historical Data
* Premium members only.
The historical data trend for Genetic Analysis AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Genetic Analysis AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Genetic Analysis AS's Share Price of today is €0.0432. Genetic Analysis AS's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Genetic Analysis AS (FRA:8V8) has a PS Ratio of 1.88 as of Jul. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genetic Analysis AS and its competitors. This is 32% below median its historical median of 2.78. Over the past decade, Genetic Analysis AS's PS Ratio has ranged from 1.07 to 71.77. According to the industry distribution chart, Genetic Analysis AS ranks #93 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 46.5%.
Is Genetic Analysis AS's PS Ratio too high?
Genetic Analysis AS's current PS Ratio of 1.88 is 32% below median its 10-year median of 2.78. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 71.77. The Medical Diagnostics & Research industry median PS Ratio is 2.72. Genetic Analysis AS's value of 1.88 is 30.9% below this industry median. Based on the distribution chart, Genetic Analysis AS ranks #93 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genetic Analysis AS has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #93 out of 200 companies for PS Ratio. This puts Genetic Analysis AS in the upper half of its industry. The industry median PS Ratio is 2.72. Genetic Analysis AS's value of 1.88 is 30.9% below this benchmark. Historically, Genetic Analysis AS's own PS Ratio has ranged from 1.07 to 71.77 over the past decade. While the company's 10-year median is 2.78 vs. the industry median of 2.72, Genetic Analysis AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.72, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetic Analysis AS's current PS Ratio of 1.88 is 30.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genetic Analysis AS and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current PS Ratio is 1.88, which is 32% below median its own 10-year median of 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Genetic Analysis AS (FRA:8V8) has a current PS Ratio of 1.88. The stock's GF Value™ is €0.04, compared to a current price of €0.04 — trading 8% above its estimated fair value. The current PS Ratio is 1.88, which is 32% below median its 10-year median of 2.78 and 30.9% below the Medical Diagnostics & Research industry median of 2.72. Genetic Analysis AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Genetic Analysis AS (FRA:8V8), the current PS Ratio is 1.88 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (FRA:8V8) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of €0.04 is trading 8% above its estimated GF Value™ of €0.04.
Key valuation signals for FRA:8V8:
PS Ratio: 1.88 (32% below median its 10-year median of 2.78)
GF Value™: €0.04 vs. price of €0.04 (8% above fair value)
Industry Position: 30.9% below the Medical Diagnostics & Research median (#93 of 200)
No single metric tells the full story. See the FRA:8V8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score
Get the complete analysis for FRA:8V8
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8V8 has been successfully added to your 
